Last reviewed · How we verify
E. Coli Cervicitis — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Fortaz | CEFTAZIDIME | Pai Holdings Pharm | ceftazidime | 1985-01-01 | ||
| Ceftazidim | Ceftazidim | Tel-Aviv Sourasky Medical Center | Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pai Holdings Pharm · 2 drugs in E. Coli Cervicitis
- Tel-Aviv Sourasky Medical Center · 1 drug in E. Coli Cervicitis
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in E. Coli Cervicitis:
- E. Coli Cervicitis treatment updates — RSS
- E. Coli Cervicitis treatment updates — Atom
- E. Coli Cervicitis treatment updates — JSON
Cite this brief
Drug Landscape (2026). E. Coli Cervicitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/e-coli-cervicitis. Accessed 2026-06-10.
Related
- E. Coli Cervicitis full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing